Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been registered by the TGA for the treatment of Australian adults with relapsed or refractory follicular lymphoma (R/R FL) (Grade 1-3a)
- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299